Clinical Trial Update: OKN-007 in Combination With Adjuvant Temozolomide Chemoradiotherapy for Newly Diagnosed Glioblastoma [Phase 1]

View source ↗

Summary

An update on a Phase 1 trial evaluating OKN-007 in combination with adjuvant temozolomide chemoradiotherapy for newly diagnosed glioblastoma; the study is curre…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Glioblastoma

Drugs mentioned

• OKN-007
• Temodar (Temozolomide)

Snippet

Sponsor: University of Oklahoma | Conditions: Glioblastoma | Phase 1 | Status: ACTIVE_NOT_RECRUITING